

Zosano Pharma Corp  
Form 8-K  
March 17, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 17, 2017**

**ZOSANO PHARMA CORPORATION**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-36570**  
**(Commission**  
**File Number)**  
**34790 Ardentech Court**

**45-4488360**  
**(I.R.S. Employer**  
**Identification No.)**

**Fremont, CA 94555**

Edgar Filing: Zosano Pharma Corp - Form 8-K  
(Address of principal executive offices) (Zip Code)

(510) 745-1200

Registrant's telephone number, including area code

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On March 17, 2017, Zosano Pharma Corporation (the Company ) filed an Issuer Free Writing Prospectus relating to the Company s Preliminary Prospectus dated March 13, 2017 (Registration No. 333-216410). A copy of the Issuer Free Writing Prospectus is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

**Number**

**Exhibit Description**

99.1	Issuer Free Writing Prospectus dated March 17, 2017 filed pursuant to Rule 433 relating to the Company s Preliminary Prospectus dated March 13, 2017 (Registration No. 333-216410).
------	---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ZOSANO PHARMA CORPORATION**

Dated: March 17, 2017

By: /s/ Georgia Erbez  
Name: Georgia Erbez  
Title: Chief Business Officer and Interim Chief  
Financial Officer

**EXHIBIT INDEX**

**Exhibit  
Number**

**Exhibit Description**

99.1	Issuer Free Writing Prospectus dated March 17, 2017 filed pursuant to Rule 433 relating to the Company's Preliminary Prospectus dated March 13, 2017 (Registration No. 333-216410).
------	---